148 related articles for article (PubMed ID: 16333039)
21. Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment.
Perrin C; Fabre C; Raoul JL; Boucher E
Acta Oncol; 2006; 45(8):1135-6. PubMed ID: 17118852
[No Abstract] [Full Text] [Related]
22. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
23. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
Dancey JE; Schoenfeldt M
Oncology (Williston Park); 2001 Jun; 15(6):748-50, 756-8. PubMed ID: 11430207
[No Abstract] [Full Text] [Related]
24. Hypomagnesaemia in oncologic patients: to treat or not to treat?
Wolf FI; Trapani V; Cittadini A; Maier JA
Magnes Res; 2009 Mar; 22(1):5-9. PubMed ID: 19441269
[TBL] [Abstract][Full Text] [Related]
25. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
26. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
27. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Cortot AB
Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
29. EGFR inhibitors square off at ASCO.
Baker M
Nat Biotechnol; 2004 Jun; 22(6):641. PubMed ID: 15175668
[No Abstract] [Full Text] [Related]
30. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
31. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target.
Meropol NJ
J Clin Oncol; 2005 Mar; 23(9):1791-3. PubMed ID: 15677698
[No Abstract] [Full Text] [Related]
33. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Perez-Soler R; Zou Y; Li T; Ling YH
Clin Cancer Res; 2011 Nov; 17(21):6766-77. PubMed ID: 21914790
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
[No Abstract] [Full Text] [Related]
35. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
36. [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Reck M; Kranich AL; Steinbach AK; Gatzemeier U
Med Klin (Munich); 2005 Dec; 100(12):785-93. PubMed ID: 16453093
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
Lacouture ME; Melosky BL
Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
[TBL] [Abstract][Full Text] [Related]
38. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
39. [EGFR/HER1: a target life].
Viel E; Curtit E; Mansi L; Vignot S
Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
[TBL] [Abstract][Full Text] [Related]
40. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]